Aeonvital, of Beijing, has closed a Series Pre-A financing round to advance human trials of its tumor-infiltrating lymphocyte (TIL) therapy candidate and preclinical trials of its therapeutic HPV vaccine. More news from Huixinyigu, Junshi, Everest, BeiGene, BI, Lilly, Luye.
Guangzhou biotech Canwell closed a Series A round of RMB200 million ($31.4 million) to advance CAN1012, a TLR7 agonist, in multiple tumor types. More news from Novastage, Bayer, Everest.
After securing COVID-19 vaccines from Providence Therapeutics, Everest Medicines now gets hold of oral drugs for the coronavirus to shore up its COVID portfolio. More news from REC Bio.
Kidney disease biotech Chinook Therapeutics has set up a joint venture called SanReno Therapeutics with an investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners Chinam, and more news from BeyondSpring, Everest, Zai Lab and ITabMed.
Everest Medicines and AbCellera entered a multi-year collaboration to discover therapeutic antibodies for up to 10 targets selected by Everest. This is the third deal Everest disclosed in two weeks.